- 3,753
- 4,198
The journal Cell published online a report showing that SARS-CoV-2, the virus that causes the COVID-19 disease, requires a host cell enzyme for entry into cells and that clinically approved inhibitors of that enzyme can inhibit virus entry in experiments with cultured cells:
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically-Proven Protease Inhibitor
Markus Hoffmann, Hannah Kleine-Weber, Simon Schroeder, Nadine Krüger, Tanja Herrler,Sandra Erichsen, Tobias S. Schiergens, Georg Herrler, Nai-Huei Wu, Andreas Nitsche, Marcel A. Müller, Christian Drosten, Stefan Pöhlmann
Cell DOI: 10.1016/j.cell.2020.02.052
https://marlin-prod.literatumonline.../research/cell/CELL_S0092-8674(20)30229-4.pdf
Abstract:
The TMPRSS2 inhibitor they use in the paper is camostat mesylate. The drug is not FDA approved for any indications, but it is approved for clinical use in Japan. Efficacy in cell culture experiments does not guarantee that the drug will be safe or effective in humans, but at least it provides another lead to test in clinical trials.
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically-Proven Protease Inhibitor
Markus Hoffmann, Hannah Kleine-Weber, Simon Schroeder, Nadine Krüger, Tanja Herrler,Sandra Erichsen, Tobias S. Schiergens, Georg Herrler, Nai-Huei Wu, Andreas Nitsche, Marcel A. Müller, Christian Drosten, Stefan Pöhlmann
Cell DOI: 10.1016/j.cell.2020.02.052
https://marlin-prod.literatumonline.../research/cell/CELL_S0092-8674(20)30229-4.pdf
Abstract:
The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor, ACE2, for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2and SARS-CoV infectionand identify a potential target for antiviral intervention.
The TMPRSS2 inhibitor they use in the paper is camostat mesylate. The drug is not FDA approved for any indications, but it is approved for clinical use in Japan. Efficacy in cell culture experiments does not guarantee that the drug will be safe or effective in humans, but at least it provides another lead to test in clinical trials.